When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Faricimab - Wikipedia

   en.wikipedia.org/wiki/Faricimab

   Faricimab is a 150kDa-sized bispecific antibody whose molecular structure allows a high affinity bond to both vascular endothelial growth factor A (VEGF-A) and Angiopoietin (Ang-2). [9] By blocking the action of these two growth factors, faricimab decreases migration and replication of endothelial cells allowing for stabilization of vascular ...

3. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [ 16 ] [ 17 ] It was developed by Regeneron Pharmaceuticals .

4. US FDA approves two biosimilars for blockbuster eye drug Eylea

   www.aol.com/news/us-fda-approves-two-biosimilars...

   The agency approved Biocon Biologics' Yesafili as well as Samsung Bioepis and Biogen's Opuviz, while also allowing interchangeability, or the drug's substitution with biosimilars without the need ...

5. Bispecific monoclonal antibody - Wikipedia

   en.wikipedia.org/wiki/Bispecific_monoclonal_antibody

   Additional bispecific antibody drugs have since been approved by the US FDA: emicizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. [31] Among the bsAb programs currently under development, the combination of CD3 and tumor surface targets are the most popular targets pairs.

6. Basis of estimate - Wikipedia

   en.wikipedia.org/wiki/Basis_of_estimate

   A pivot table in BOEMax, a Basis of Estimate software package. To create a BOE companies, throughout the past few decades, have used spreadsheet programs and skilled cost analysts to enter thousands of lines of data and create complex algorithms to calculate the costs. These positions require a high level of skill to ensure accuracy and ...

7. Cost-effectiveness analysis - Wikipedia

   en.wikipedia.org/wiki/Cost-effectiveness_analysis

   A 1995 study of the cost-effectiveness of reviewed over 500 life-saving interventions found that the median cost-effectiveness was $42,000 per life-year saved. [7] A 2006 systematic review found that industry-funded studies often concluded with cost-effective ratios below $20,000 per QALY and low quality studies and those conducted outside the ...

8. Cost-plus pricing - Wikipedia

   en.wikipedia.org/wiki/Cost-plus_pricing

   Markup price = (unit cost * markup percentage) Markup price = $450 * 0.12 Markup price = $54 Sales Price = unit cost + markup price. Sales Price= $450 + $54 Sales Price = $504 Ultimately, the $54 markup price is the shop's margin of profit. Cost-plus pricing is common and there are many examples where the margin is transparent to buyers. [4]

9. Intention-to-treat analysis - Wikipedia

   en.wikipedia.org/wiki/Intention-to-treat_analysis

   In an ITT population, none of the patients are excluded and the patients are analyzed according to the randomization scheme. In other words, for the purposes of ITT analysis, everyone who is randomized in the trial is considered to be part of the trial regardless of whether he or she is dosed or completes the trial.